More about

Giant Cell Arteritis

News
March 31, 2023
1 min read
Save

Top in rheumatology: Tocilizumab for giant cell arteritis; glucocorticoids for MIS-C

Top in rheumatology: Tocilizumab for giant cell arteritis; glucocorticoids for MIS-C

The European Alliance of Associations for Rheumatology issued updated guidance recommending weekly tocilizumab, along with glucocorticoids that should eventually be tapered, for patients with new, relapsing giant cell arteritis.

News
March 23, 2023
3 min read
Save

EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis

EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

News
January 26, 2023
2 min read
Save

One-third of patients hospitalized for GCA require readmission within 6 months

One-third of patients hospitalized for GCA require readmission within 6 months

Patients with giant cell arteritis may require unexpected and sudden care, with as many as one-third requiring readmission to a health care center within 6 months of an episode, according to data published in Arthritis Care & Research.

News
December 10, 2021
1 min read
Save

Top in rheumatology: Dermatomyositis prevalence, self-management of arthritis

Top in rheumatology: Dermatomyositis prevalence, self-management of arthritis

Recent data found that dermatomyositis was more prevalent than had been thought. The retrospective, population-based cohort study that led to this conclusion was the top story in rheumatology last week.

News
December 07, 2021
2 min read
Save

Tocilizumab delays flare, reduces glucocorticoid dose in new-onset giant cell arteritis

Tocilizumab delays flare, reduces glucocorticoid dose in new-onset giant cell arteritis

Weekly tocilizumab delays initial flare and reduces glucocorticoid exposure in patients with relapsing and new-onset giant cell arteritis, according to data published in Rheumatology.

News
November 30, 2021
2 min read
Save

Vascular ultrasound may offer first-line alternative for diagnosing giant cell arteritis

Vascular ultrasound may offer first-line alternative for diagnosing giant cell arteritis

Vascular ultrasound, using high-end equipment and optimized settings, may be an effective replacement for temporal artery biopsy as a first-line diagnostic tool in patients with suspected giant cell arteritis, according to a Danish study.

News
November 10, 2021
3 min read
Save

'Advanced vascular imaging' drives revision to ACR/EULAR vasculitis classification criteria

'Advanced vascular imaging' drives revision to ACR/EULAR vasculitis classification criteria

The American College of Rheumatology and EULAR have updated classification criteria for five types of large- and small-vessel vasculitis, driven in part by advances in diagnostic imaging, according to presenters at ACR Convergence 2021.

News
October 07, 2021
7 min read
Save

Older woman presents with progressive diplopia, eye redness and proptosis

Older woman presents with progressive diplopia, eye redness and proptosis

A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months of progressive diplopia, bilateral eye redness and proptosis.

News
September 01, 2021
1 min read
Save

Nationwide study confirms elderly, female, white populations have higher incidence of GCA

Nationwide study confirms elderly, female, white populations have higher incidence of GCA

Older, white and female populations are at the highest risk for developing giant cell arteritis, according to research presented at the Women in Ophthalmology Summer Symposium.

News
August 19, 2021
4 min read
Save

Cancer screening recommendations in autoimmune disease rely on experience in lieu of data

Cancer screening recommendations in autoimmune disease rely on experience in lieu of data

Cancer screening recommendations for patients with autoimmune diseases largely rely on clinical experience and extrapolation in the absence of abundant data, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

View more